**Figure 4 source data. Epithelial cell lines established from mouse and human prostate tissue.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **A. Renal grafts using 1 x 105 cells (APCA or ADCA cell lines)** | | | | | | |
| Line | Tamoxifen | Total | Recovered | | | Phenotype |
| AR+ | AR+/AR– | AR– |
| APCA-1 | No | 5 | 5 | – | – | Large and small glands, some with secretions |
| APCA-1 | Yes | 6 | – | 2 | – | Few glands present |
| APCA-2 | No | 5 | 5 | – | – | Large and small glands, some with secretions |
| APCA-2 | Yes | 6 | 2 | 1 | – | Few glands present |
| ADCA-1 | No | 6 | – | – | 4 | Large and small glands without secretions |

**B. Human prostate epithelial cell lines established as adherent cultures.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Line** | **Source** | **Sorting strategy** | **DHT** | | **Passage** |
| HPE-1 | Radical prostatectomy 23 | EpCAM+/Ecad+ | No | P6 | |
| HPE-2 | Radical prostatectomy 23 | EpCAM+/Ecad+ | Yes | P6 | |
| HPE-3 | Radical prostatectomy 24 | EpCAM+/Ecad+ | Yes | | P8 |
| HPE-4 | Radical prostatectomy 25 | No sort | Yes | | P7 |
| HPE-5 | Radical prostatectomy 25 | EpCAM+/Ecad+ | Yes | | P5 |
| HPE-6 | Radical prostatectomy 25 | EpCAM+/Ecad+/Ngfr+ | Yes | | P7 |
| HPE-7 | Radical prostatectomy 25 | EpCAM+/Ecad+/Cd24+ | Yes | | P6 |
| HPE-8 | Radical prostatectomy 26 | No sort | Yes | | P5 |
| HPE-9 | Radical prostatectomy 26 | EpCAM+/Ecad+ | Yes | | P5 |
| HPE-10 | Radical prostatectomy 26 | EpCAM+/Ecad+/Cd24+ | Yes | | P7 |
| HPE-11 | Radical prostatectomy 26 | EpCAM+/Ecad+/Agr2+ | Yes | | P7 |
| HPE-12 | Radical prostatectomy 27 | No sort | Yes | | P4 | |
| HPE-13 | Radical prostatectomy 27 | EpCAM+/Ecad+ | Yes | | P4 | |
| HPE-14 | Radical prostatectomy 27 | EpCAM+/Ecad+/Cd24+ | Yes | | P4 | |

Lines were established using benign human prostate epithelial cells that were unsorted or were sorted by selection for EpCAM+ and/or E-cadherin+ (Ecad+) positive cells. Where noted, cells were further sorted for expression of Nerve growth factor receptor (Ngfr), Cd24, or Anterior gradient 2 (Agr2).